Evaluation of Patients' Satisfaction With the Dispensation of Their Oral Anticancer Treatment in Community Pharmacy
ORCA
2 other identifiers
observational
104
1 country
1
Brief Summary
The pharmacist, as a specialist of medications, occupies a strategic position: he participates in a global care of their patients. Dispensation is the pharmaceutical act which associates with the dispensing of medications "the pharmaceutical analysis of the medical prescription if it exists, the possible preparation of the doses to be administered and the provisions of the information and advices necessary for the proper use of medications". The pharmacist ensures that the quality and safety of the dispensation is guaranteed at all times by limiting as far as possible the risks associated with an error in delivery, prescription, drug interactions or undetected contraindications, inadequate dosages or non-compliance with treatment. The longer the patient feels satisfied with the stage of delivery of his treatment, the better his adherence to treatment is, and the less he will encounter poor compliance. Oncology has particularly benefited in recent years from the introduction of numerous drugs with the aim of extending the duration of response in a growing number of indications. Traditionally in oncology, chemotherapy treatments are administered intravenously by trained personnel and rarely managed by the patient at home. Recently, there has been a growing choice of oral formulations, whether for conventional hormonal, anticancer therapies or targeted therapies. These specialties are now widely available in community pharmacies. Oral administration puts the patient at the center of his therapeutic management. He must take his medication alone. Adherence and compliance are therefore particularly important here for an optimal risk-benefit ratio. This study project is designed to evaluate the satisfaction of patients undergoing oral chemotherapy treated for a cancer pathology and whose treatment is provided by their community pharmacies. It also needs to provide information about the reasons for their poor adherence to treatment (personal factors, factors attributable to treatment, factors attributable to the care system). Patients will be recruited and interviewed by contacting several departments of the Clermont-Ferrand University Hospital (CHU de Clermont-Ferrand), who are used to caring for patients with cancerous diseases (hematology, urology, respiratory, gastro-enterology). The data collected in this study may be used for subsequent studies evaluating new management strategies or therapeutic education to improve adherence to patient treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jun 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 20, 2017
CompletedFirst Submitted
Initial submission to the registry
July 31, 2017
CompletedFirst Posted
Study publicly available on registry
September 7, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 11, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
April 11, 2019
CompletedJune 6, 2022
October 1, 2018
1.8 years
July 31, 2017
June 3, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Assessment of patients' satisfaction with the dispensation of their oral anticancer treatments in community pharmacy
(visual analogic scale 0-100)
at day 1
Secondary Outcomes (5)
Assessment of patients' satisfaction based on Quality of Information Provided by Oncologists and Pharmacists
at day 1
Assessment of patients' satisfaction based on type of cancer
at day 1
Assessment of patients' satisfaction based on type of treatment received
at day 1
Assessment of patients' satisfaction based on number of medications taken per day
at day 1
Assessment of patients' satisfaction based on patient characteristics
at day 1
Study Arms (1)
Patients with cancer chemotherapy
This study project is designed to evaluate the satisfaction of patients undergoing oral chemotherapy treated for a cancer and whose treatment is provided by their community pharmacies.
Interventions
All the oral medications for cancer treatment (hormonal, cytotoxic and targeted therapies)
Eligibility Criteria
This study project is designed to evaluate the satisfaction of patients undergoing oral chemotherapy treated for a cancer pathology and whose treatment is provided by their community pharmacies. It also needs to provide information about the reasons for their poor adherence to treatment (personal factors, factors attributable to treatment, factors attributable to the care system).
You may qualify if:
- Patient (or helping people) receiving oral cancer chemotherapy or oral hormone therapy delivered in community pharmacy for the treatment of cancer
- Non-opposition to participation in the study
You may not qualify if:
- Patient unable to understand or respond to questionnaires
- Age \< 18
- Legal incapacity (person deprived of liberty or under guardianship)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU de Clermont-Ferrand
Clermont-Ferrand, Auvergne, 63003, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
David BALAYSSAC, PhD, PharmD
CHU de Clermont-Ferrand
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 31, 2017
First Posted
September 7, 2017
Study Start
June 20, 2017
Primary Completion
April 11, 2019
Study Completion
April 11, 2019
Last Updated
June 6, 2022
Record last verified: 2018-10